BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 10, 2006
View Archived Issues
Elan Sells European Prialt Rights To Eisai For $100M
Elan Corp. plc decided to sell the European rights to its pain product Prialt, but is keeping U.S. rights, where the drug already is being sold. (BioWorld Today)
Read More
Inflabloc Adds Cancer Drugs Through Merger, Raises $6M
Read More
Diversified Risk Important To Investors In Stem Cells
Read More
Series A Now Done, Proacta Has Funds To Fight Tumors
Read More
Other News To Note
Read More
Clinic Roundup
Read More